Company / Book Value per Share
Regeneron Pharmaceuticals Book Value per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Book Value per Share
$274.907
FY2025
5-year range
$95.789 / $274.907
FY2021-FY2025
Trend
+6.3%
vs FY2024
Sector context
#3 of 209
Health Care
What the data says
Among 209 Health Care companies, Regeneron Pharmaceuticals is in the top 1% for book value per share. Book Value per Share has increased for 3 consecutive years, from $95.789 in FY2022 to $274.907 in FY2025.
Based on SEC 10-K filings.
$274.907 in FY2025 with a 5-year CAGR of +29.2%. Ranks 3rd among 209 companies in Health Care.
Improved from $231.489 to $274.907 over the past 2 years.
Health Care sector context is included.
Book Value per Share over time
Growth rates
- 3-Year CAGR
- +42.1%
- 5-Year CAGR
- +29.2%
- 10-Year CAGR
- -
Sector benchmark
+45.1% above sector average
Key checks
Key Insights
- Regeneron Pharmaceuticals's book value per share has grown for 3 consecutive years.
- 5-year CAGR of +29.2%, indicating consistent growth.
- In FY2025, book value per share increased 6.3% year-over-year.
- Ranks #3 out of 209 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 3.03 (safe zone, above 2.9 threshold)
- Strong profit margin: 32.1%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Book Value per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $274.907 | +6.3% |
| FY2024 | $258.622 | +11.7% |
| FY2023 | $231.489 | +141.7% |
| FY2022 | $95.789 | -1.0% |
| FY2021 | $96.769 | +26.9% |
| FY2020 | $76.283 | -20.3% |
| FY2019 | $95.683 | +27.1% |
| FY2018 | $75.299 | +41.2% |
| FY2017 | $53.32 | +35.9% |
| FY2016 | $39.231 | +19.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026